Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

OBJECTIVE: This 24-week, double-blinded, phase 3 clinical trial (DEPICT-2; ClinicalTrials.gov, NCT02460978) evaluated efficacy and safety of dapagliflozin as adjunct therapy to adjustable insulin in patients with inadequately controlled type 1 diabetes (HbA1c 7.5-10.5%). RESEARCH DESIGN AND METHODS:...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	DIABETES CARE 2018-09, Vol.41 (9), p.1938-1946
Hauptverfasser:	Mathieu, Chantal, Dandona, Paresh, Gillard, Pieter, Senior, Peter, Hasslacher, Christoph, Araki, Eiichi, Lind, Marcus, Bain, Stephen C, Jabbour, Serge, Arya, Niki, Hansen, Lars, Thoren, Fredrik, Langkilde, Anna Maria
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!